Compare Inovio Pharmaceuticals Inc (INO) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Ulta Beauty Inc trades at $565.99 (market cap $24.12B). The key difference: Ulta Beauty Inc is far larger — about 215× Inovio Pharmaceuticals Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Ulta Beauty Inc for 92 Days on average.
| INO | ULTA | |
|---|---|---|
Market Cap | $112.19M | $24.12B |
Volume | 3,201,278 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $706.82 |
52-Week Low | $0.66 | $450.75 |
Typical Hold Time | 43 Days | 92 Days |
Enterprise Value | $83.51M | $26.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
ULTA Beauty trades at $545.48, down 0.33% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings beat and raised 2026 guidance, though Q4 2025 missed expectations. Valuation metrics show a P/E of 20.55 and P/S of 1.92, with robust profitability including 46.12% ROE. Analyst consensus is strongly bullish with 59.57% buy ratings and a $624.93 price target, representing 14.6% upside potential.
ULTA presents a compelling growth story with e-commerce momentum and expansion into wellness categories, though margin compression and flat traffic pose near-term challenges. The stock offers attractive upside to analyst targets but faces execution risks amid consumer spending pressures. Institutional ownership remains strong with recent buying activity from major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
